(Q30808014)

26 June 2017

title

Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

26 June 2017

main subject

0 references

author name string

Carrie M Hersh

series ordinal

1

1 reference

26 June 2017

Jeffrey A Cohen

series ordinal

2

1 reference

26 June 2017

publication date

1 January 2014

1 reference

26 June 2017

1 reference

26 June 2017

volume

6

1 reference

26 June 2017

issue

3

1 reference

26 June 2017

page(s)

249-259

1 reference

26 June 2017

1 reference

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

21 January 2018

1 reference

Immunopathology of secondary-progressive multiple sclerosis.

21 January 2018

1 reference

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

21 January 2018

1 reference

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

The CD52 antigen and development of the CAMPATH antibodies

21 January 2018

1 reference

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

21 January 2018

1 reference

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

21 January 2018

1 reference

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

21 January 2018

1 reference

Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart

21 January 2018

1 reference

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

21 January 2018

1 reference

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells

21 January 2018

1 reference

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

21 January 2018

1 reference

Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity

21 January 2018

1 reference

Drugs in development for relapsing multiple sclerosis

21 January 2018

1 reference

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

21 January 2018

1 reference

Pharmacokinetics of CAMPATH-1H: assay development and validation

21 January 2018

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

Reshaping human antibodies for therapy

21 January 2018

1 reference

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis

21 January 2018

1 reference

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

21 January 2018

1 reference

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

21 January 2018

1 reference

Hemi-seesaw nystagmus in lateral medullary syndrome

21 January 2018

1 reference

Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

Alemtuzumab therapy for multiple sclerosis

21 January 2018

1 reference

Immune competence after alemtuzumab treatment of multiple sclerosis

21 January 2018

1 reference

Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.14.7

1 reference

26 June 2017

1 reference